CIAM
GYRE icon

Caitong International Asset Management’s Gyre Therapeutics GYRE Stock Holding History

Caitong International Asset Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21 Buy
+3
New +$23 ﹤0.01% 2073

Other funds holding GYRE

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Caitong International Asset Management's GYRE Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Gyre Therapeutics (GYRE) in Q1 2026: 3 shares worth $21. The stake represents ﹤0.01% of the portfolio and ranks #2073 among its holdings.

56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.

  • Caitong International Asset Management held 3 shares of Gyre Therapeutics worth $21 as of Q1 2026.
  • Gyre Therapeutics was a new Caitong International Asset Management position in Q1 2026.
  • Gyre Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2073 holding.
  • 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.